Clinical Report: Impact of SGLT2 Inhibitors on Microscopic Hematuria in IgAN

Overview

This report examines the role of SGLT2 inhibitors in managing microscopic hematuria in IgA nephropathy (IgAN).

Background

IgA nephropathy is the most prevalent primary glomerulonephritis globally, with significant implications for patient outcomes. Microscopic hematuria is increasingly recognized as a predictor of disease progression, yet its assessment in treatment response has been limited. SGLT2 inhibitors have been studied for their effects on kidney function and proteinuria in IgAN patients.

Data Highlights

No numerical data or trial results were provided in the source material.

Key Findings

• Microscopic hematuria is an independent predictor of disease progression in IgAN.
• SGLT2 inhibitors have been shown to reduce proteinuria and slow kidney function decline in IgAN patients.
• Current clinical trials and guidelines primarily focus on proteinuria and eGFR.
• Hematuria may indicate glomerular inflammatory activity.
• There is a need for dedicated prospective studies to evaluate the effects of SGLT2 inhibitors on hematuria.

Clinical Implications

Further research is necessary to clarify the effects of SGLT2 inhibitors on hematuria.

Conclusion

Future studies are essential to understand the implications of SGLT2 inhibitors on hematuria.

Related Resources & Content

1. KDIGO, KDIGO, 2025 -- Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)
2. Frontiers in Medicine, Frontiers, 2026 -- Efficacy of SGLT2 inhibitors in preventing end-stage kidney disease in patients with IgA nephropathy: a scoping review
3. JAMA Network Open — Pharmacist Outreach and SGLT2 Inhibitor Uptake in Patients With Diabetes and Chronic Kidney Disease
4. The New Gastroenterologist — SGLT2 Inhibitors Show Potential Benefits for Diuretic-Treated Patients With Cirrhosis
5. Drugs - Real World Outcomes — Association of Sodium-Glucose Cotransporter-2 Inhibitors with Decreased Heart Failure Hospitalization Risk in Patients with Preserved Ejection Fraction and Type 2 Diabetes Mellitus: Insights from a Diverse Urban Cohort Study
6. Pharmacist Outreach and SGLT2 Inhibitor Uptake in Patients With Diabetes and Chronic Kidney Disease
7. SGLT2 Inhibitors Show Potential Benefits for Diuretic-Treated Patients With Cirrhosis
8. Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)
9. S U P P L E M E N T TO
10. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy - ScienceDirect
11. Empagliflozin in Patients with Chronic Kidney Disease | New England Journal of Medicine
12. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial - ScienceDirect
13. https://www.empakidney.org/downloads/secondaryanalysisempa-kidney_supplement_2023-12-04.pdf
14. Microscopic hematuria in IgA nephropathy: a biomarker of disease activity | Clinical Kidney Journal | Oxford Academic
15. Frontiers | Efficacy of SGLT2 inhibitors in preventing end-stage kidney disease in patients with IgA nephropathy: a scoping review